Stockscreener 앱 받기
1.72
6.52%
-0.12
시간 외 거래:
1.73
0.01
+0.58%
전일 마감가:
$1.84
열려 있는:
$1.79
하루 거래량:
35,304
Relative Volume:
0.14
시가총액:
$16.80M
수익:
-
순이익/손실:
$-19.44M
주가수익비율:
-0.647
EPS:
-2.6585
순현금흐름:
$-12.71M
1주 성능:
-9.95%
1개월 성능:
+7.50%
6개월 성능:
-14.00%
1년 성능:
-75.70%
1일 변동 폭
$1.70
$1.84
1주일 범위
$1.70
$2.11
52주 변동 폭
$1.17
$7.50
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.72 | 17.97M | 0 | -19.44M | -12.71M | -2.6585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
LeonaBio (ATHA) wins approval for 2026 equity plan and major share increase - Stock Titan
[144] KALA BIO, Inc. SEC Filing - Stock Titan
Gossamer Bio (NASDAQ: GOSS) 2025 loss widens as seralutinib Phase 3 misses goal - Stock Titan
Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan
Kyntra Bio (Nasdaq: KYNB) unveils 2025 results, FG-3246 and roxadustat plans - Stock Titan
INmune Bio Receives $8 Consensus Price Target from Analysts - National Today
[8-K] Bio Green Med Solution, Inc. Reports Material Event | BGMS SEC FilingForm 8-K - Stock Titan
CyPath Lung growth accelerates while bioAffinity (NASDAQ: BIAF) posts larger 2025 loss - Stock Titan
Morgan Stanley Smith Barney files Form 144 to sell restricted KALA shares (KALA) - Stock Titan
Adicet Bio (NASDAQ: ACET) outlines 2025 loss and cash runway into 2027 - Stock Titan
Korro Bio (NASDAQ: KRRO) expands RNA-editing pipeline as 2025 net loss deepens - Stock Titan
Form 144: Restricted stock sale notice — Kala Pharmaceuticals (NASDAQ: KALA) - Stock Titan
Layoff Tracker: Vistagen, Evotec, Reckitt Benckiser Downsize, Collectively Affecting Hundreds - BioSpace
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
$180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
Korro Bio Raises $85 Million in Private Placement, Adds Investor Registration Rights - TradingView
Korro Bio (KRRO) secures $85M PIPE to extend cash runway into 2028 - Stock Titan
Boundless Bio (Nasdaq: BOLD) trims 2025 loss, funds KOMODO-1 into 2028 - Stock Titan
Annovis Bio Stock Price Drops 8.5%What's Next? - National Today
Climb Bio (Nasdaq: CLYM) ends 2025 with $160.7M cash and key 2026 trial readouts ahead - Stock Titan
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
KALA BIO (NASDAQ: KALA) signs exclusive Researgency AI license and $55M Younet option - Stock Titan
Bank license renewal backs BIO-key (NASDAQ: BKYI) biometric growth - Stock Titan
Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Rises By 20.2% - MarketBeat
CABA SEC FilingsCabaletta Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
bioAffinity Technologies (NASDAQ: BIAF) shows asthma and COPD diagnostic data - Stock Titan
Passage Bio (NASDAQ: PASG) narrows 2025 loss and advances PBFT02 trial - Stock Titan
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
IBTROZI launch lifts Nuvation Bio (NUVB) 2025 revenue while losses narrow - Stock Titan
683 Capital reports 5.23% stake in Gossamer Bio | GOSS SEC FilingForm SCHEDULE 13G - Stock Titan
Adicet Bio Inc expected to post a loss of $2.80 a shareEarnings Preview - TradingView
QTTB SEC FilingsQ32 BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Belite Bio Inc expected to post a loss of 55 cents a shareEarnings Preview - TradingView
INmune Bio (NASDAQ: INMB) outlines RDEB and Alzheimer’s trial paths - Stock Titan
Inmune Bio furnishes corporate presentation detailing CORDStrom and XPro1595 development plans - TradingView
Zura Bio (ZURA) revises Ogier legal opinion and consent in 8-K/A - Stock Titan
BOLD SEC FilingsBOUNDLESS BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
TRML SEC FilingsTourmaline Bio 10-K, 10-Q, 8-K Forms - Stock Titan
New CyPath Lung validation study at BAMC by bioAffinity (BIAF) - Stock Titan
TELA SEC FilingsTela Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Reduction | GOSS Stock News - GuruFocus
BioMarin’s top execs schedule four investor events in March - Stock Titan
Construction giant brings drug tests in-house with fingerprint scans at UK sites - Stock Titan
BIO-key to secure Mozambique digital payments for 36.6M people - Stock Titan
Bio-Path (BPTH) grants CEO affiliate new preferred shares and weighs trial restarts - Stock Titan
Axsome Therapeutics, Inc. SEC 10-K Report - TradingView
BioMarin (BMRN) grows 2025 revenue 13% and guides 2026 EPS to $4.95–$5.15 - Stock Titan
Inclement weather delays PROCEPT BioRobotics Q4 call, Investor Day - Stock Titan
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):